Company’s 36-month beta value is -1.51.Analysts have differing opinions on the stock, with 8 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 1 as “sell.”
The public float for DAWN is 59.16M, and currently, short sellers hold a 22.94% ratio of that floaft. The average trading volume of DAWN on August 28, 2024 was 1.01M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DAWN) stock’s latest price update
Day One Biopharmaceuticals Inc (NASDAQ: DAWN)’s stock price has decreased by -0.60 compared to its previous closing price of 14.08. However, the company has seen a -1.44% decrease in its stock price over the last five trading sessions. investorplace.com reported 2024-08-14 that When volatility strikes the stock market as it sets new highs, investors get nervous. Wild swings in price can often signal a market top.
DAWN’s Market Performance
Day One Biopharmaceuticals Inc (DAWN) has seen a -1.44% fall in stock performance for the week, with a -7.87% decline in the past month and a 1.71% surge in the past quarter. The volatility ratio for the week is 3.29%, and the volatility levels for the past 30 days are at 5.26% for DAWN. The simple moving average for the last 20 days is 1.84% for DAWN stock, with a simple moving average of -2.58% for the last 200 days.
Analysts’ Opinion of DAWN
Many brokerage firms have already submitted their reports for DAWN stocks, with BofA Securities repeating the rating for DAWN by listing it as a “Buy.” The predicted price for DAWN in the upcoming period, according to BofA Securities is $24 based on the research report published on August 01, 2024 of the current year 2024.
Needham, on the other hand, stated in their research note that they expect to see DAWN reach a price target of $33, previously predicting the price at $30. The rating they have provided for DAWN stocks is “Buy” according to the report published on April 24th, 2024.
BofA Securities gave a rating of “Underperform” to DAWN, setting the target price at $9 in the report published on April 25th of the previous year.
DAWN Trading at -1.43% from the 50-Day Moving Average
After a stumble in the market that brought DAWN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -22.55% of loss for the given period.
Volatility was left at 5.26%, however, over the last 30 days, the volatility rate increased by 3.29%, as shares sank -2.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.04% upper at present.
During the last 5 trading sessions, DAWN fell by -1.69%, which changed the moving average for the period of 200-days by +24.42% in comparison to the 20-day moving average, which settled at $13.73. In addition, Day One Biopharmaceuticals Inc saw -4.14% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DAWN starting from Dubow Adam, who sale 3,202 shares at the price of $14.00 back on Aug 16 ’24. After this action, Dubow Adam now owns 26,928 shares of Day One Biopharmaceuticals Inc, valued at $44,825 using the latest closing price.
York Charles N II, the COO, CFO AND SECRETARY of Day One Biopharmaceuticals Inc, sale 2,633 shares at $14.00 during a trade that took place back on Aug 16 ’24, which means that York Charles N II is holding 232,485 shares at $36,860 based on the most recent closing price.
Stock Fundamentals for DAWN
Current profitability levels for the company are sitting at:
- -33.42 for the present operating margin
- 0.86 for the gross margin
The net margin for Day One Biopharmaceuticals Inc stands at -19.14. The total capital return value is set at -0.95. Equity return is now at value -45.71, with -39.35 for asset returns.
Based on Day One Biopharmaceuticals Inc (DAWN), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -933.13. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is -84.5.
Currently, EBITDA for the company is -205.68 million with net debt to EBITDA at 0.81. When we switch over and look at the enterprise to sales, we see a ratio of 112.13. The receivables turnover for the company is 0.96for trailing twelve months and the total asset turnover is 0.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.09.
Conclusion
In a nutshell, Day One Biopharmaceuticals Inc (DAWN) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
